Boehringer drugs fail to prevent stroke recurrence in study
Micardis, a hypertension medicine from Boehringer Ingelheim Corp., failed to outperform placebo in protecting patients from stroke recurrence or reducing the risk of diabetes in a company-funded study. The clinical trial, which involved 20,332 participants, also showed that combining Boehringer's blood thinner Aggrenox with aspirin was no better than Plavix -- a rival drug from Bristol-Myers Squibb Co. and Sanofi-Aventis -- in preventing repeat strokes.
Bloomberg | 08/28
This story published in AANP SmartBrief on 08/28/2008
More from SmartBrief:
Studies: AstraZeneca, Boehringer drugs beat older blood thinners
Monday, August 31, 2009
Boehringer banks on experimental drug for female sexual dysfunction
Friday, November 13, 2009
Get stories like these delivered daily for FREE:
|
AANP SmartBrief
Designed specifically for nurse practitioners and health care professionals like you, AANP SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important health care issues. Learn more |
|